A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma-Reference-Cited by-同舟云学术

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Published:2019-01-28 Issue:7 Volume:125 Page:1113-1123
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Ott Patrick A.¹,Pavlick Anna C.²,Johnson Douglas B.³,Hart Lowell L.⁴,Infante Jeffrey R.⁵,Luke Jason J.⁶,Lutzky Jose⁷,Rothschild Neal E.⁸,Spitler Lynn E.⁹,Cowey C. Lance¹⁰,Alizadeh Aaron R.¹¹,Salama April K.¹²,He Yi¹³,Hawthorne Thomas R.¹³,Bagley Rebecca G.¹³,Zhang Joshua¹³,Turner Christopher D.¹³,Hamid Omid¹⁴

Affiliation:

1. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts

2. Department of Medical Oncology New York University School of Medicine New York New York

3. Department of Hematology/Oncology Vanderbilt‐Ingram Cancer Center Nashville Tennessee

4. Florida Cancer Specialists and Research Institute Fort Myers, Florida

5. Tennessee Oncology PLLC Nashville Tennessee

6. Department of Hematology/Oncology University of Chicago Medical Center Chicago Illinois

7. Mount Sinai Comprehensive Cancer Center Miami Beach, Florida

8. Florida Cancer Specialists West Palm Beach, Florida

9. St. Mary's Medical Center San Francisco California

10. Northern California Melanoma Center, Baylor University Medical Center Dallas Texas

11. Northside Hospital Cancer Institute Decatur Georgia